InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
09 nov. 2022 07h40 HE
|
InflaRx N.V.
Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiatedStudy designed as single ascending dose to determine safety, tolerability and...